Galena Biopharma Inc (GALE) announced its most recent quarterly financial results on Wednesday, Mar-15-2017. GALE said it had a profit of $-0.17 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.35. Analysts had a consensus of $-0.52. During the same quarter in the previous year, the company posted $-0.07 EPS.
Based on several research reports , Shares were Downgraded by FBR & Co. on Feb 6, 2017 to ” Mkt Perform” and Lowered the Price Target to $ 4 from a previous price target of $11 .Galena Biopharma Inc was Downgraded by Maxim Group to ” Hold” on Feb 2, 2017.
Several company insiders have filed Insider transactions , on Jun 7, 2016, Ryan Dunlap (Former Chief Financial Officer) sold 126,875 shares at $2.18 per share price.
Galena Biopharma Inc opened for trading at $0.54 and hit $0.587 on the upside on Wednesday, eventually ending the session at $0.5808, with a gain of 5.81% or 0.0319 points. The heightened volatility saw the trading volume jump to 16,59,051 shares. Company has a market cap of $21 M.
Galena Biopharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets including immunotherapy program led by its lead product NeuVax (nelipepimut-S) which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.